The first paragraph in the shareholder letter by Dr. Hirsch should remove any doubt as to what the company's plans are with regards to their cream and any other product. They will not be introducing any product in the market that will be sold over the counter. What will differentiate them from a myriad of other companies and products is that theirs will be:

fully validated medical products and pharmaceuticals based on cannabis.

What this means is that their most likely product that will start generating revenue is their sublingual soluble tablet. This is what I posted on January 18th:

Quote:

---

Potentially, I think the cannabinoid-enriched sublingual soluble tablet is the sleeper that will start generating revenue before anything else.

https://www.prnewswire.com/news-releases/owc-...68089.html

The above December, 2018 press release stated:
Quote:
In addition, OWCP has applied for an amendment to its study protocols to enable the comparison of its tablet with a known cannabis-based pharmaceutical, which is registered for treatment of spasticity in Multiple Sclerosis patients.

What I didn’t realize is that the pharmaceutical they were referring to is the nabixomols by GW Pharmaceuticals, sold under the trade name Sativex.
If the results showed that our Company’s soluble tablet was more effective, I think it would be the needed catalyst to turn the sp in a new direction, and change the mood of its long suffering investors forever!

---